News

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing ...
Medscape17h
Perioperative Pembrolizumab’s Strong Results for HNSCC Raise Questions
The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...
The American Journal of Managed Care8d
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...
Targeted Oncology6d
New Standard of Care? KEYNOTE-689 Results in LA-HNSCC
Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...
Physician's Weekly13d
ADORA2B Expression Predicts Prognosis and Therapy Response in HNSC
The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...
CURE11d
Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...
Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium ...